SCHEMBL2004796

SCHEMBL2004796

Cc1ccc2c(c1)c(C(=O)c1nc(-c3cccnc3)no1)c(Cl)n2Cc1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
GSK3B P49841 9/20 0.42
PTGES2 Q9H7Z7 1/20 0.42
FAAH O00519 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006062 0.93 CYP1A2 (0.48) CYP1A2CYP3A4GAACYP2D6CYP2C9
SCHEMBL2008785 0.91 GAA (0.46) CYP1A2CYP3A4GAACYP2D6CYP2C9
SCHEMBL2000134 0.91 KMT2A (0.42) L3MBTL1PTGES2FAAHSMN1; SMN2TP53
SCHEMBL2003553 0.90 GSK3B (0.42) CYP1A2CYP3A4GAACYP2D6CYP2C9
SCHEMBL1997418 0.90 CYP3A4 (0.43) CYP1A2CYP3A4GAACYP2D6CYP2C9
SCHEMBL2003986 0.90 TP53 (0.47) CYP2C9GSK3BFAAHSMN1; SMN2TP53
SCHEMBL2004618 0.90 PTGES2 (0.43) CYP1A2CYP3A4GAACYP2D6CYP2C9
SCHEMBL2000496 0.89 FAAH (0.42) CYP1A2CYP3A4CYP2C9CYP2C19PTGES2
SCHEMBL2002528 0.89 CYP1A2 (0.48) CYP1A2CYP3A4GAACYP2D6CYP2C9
SCHEMBL2004059 0.88 S1PR1 (0.46) CYP1A2CYP3A4GAACYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT CYP1A2 360/4885CYP3A4 618/4885GAA 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.